[Email This]

Vioxx Drug Safety Hearings

FDA, Merck and Vioxx:
Putting Patient Safety First?

Testimony Before the U.S. Senate Finance Committee


November 18, 2004

These files are in PDF format and can be viewed using Adobe Acrobat Reader.

Member Statements    
Witness Statements
     Panel I
Resources for the Public
  • Vioxx Information
  • Defective and Dangerous Products: Legal Issues
  • Getting Help Now
    • Dr. David J. Graham, MPH, Associate Director for Science, Office of Drug Safety, Center for Drug Evaluation and Research, U.S. Department of Health and Human Services, Food and Drug Administration, Washington, DC
         Panel II
    • Dr. Gurkirpal Singh, Adjunct Clinical Professor of Medicine, Division of Gastroenterology and Hepatology, Department of Medicine, Stanford University School of Medicine, Stanford, CA

    • Dr. Bruce M. Psaty, PhD, Professor, Medicine & Epidemiology, University of Washington, Cardiovascular Health Research Unit, Seattle, WA

         Panel III
    Tools for Corporate Counsel
  • Drugs & Biotech for Corporate Counsel
  • Class Action Defense
  • Drug Regulatory News
    • Dr. Sandra L. Kweder, Acting Director, Office of New Drugs, Center for Drug Evaluation and Research, U.S. Department of Health and Human Services, Food and Drug Administration, Washington, DC
         Panel IV

     

    To view PDF files listed on this page you will need Adobe Acrobat Reader